The
“New” Way Forward: DelveInsight’s Oncology-Based MOA Pipeline Reports
After successfully
launching a huge portfolio of Pipeline Reports under brand name Pharm Insights
covering 700+ Mechanism of Action reports; Delhi based DelveInsight is now venturing
into the market for Oncologic drugs which is expected to be among the top
revenue generating industries worldwide till 2020 through its Oncology based
Mechanism Of Action (MOA) Reports which provide comprehensive review of current
trends in the oncology market along with updated information on the latest
innovations in therapeutics based on a particular Mechanism Of Action (MOA).
DelveInsight's released
Oncology based Mechanism of Action (MOA) reports provides the targets-mode of
action based information-across all the therapy under research work, pipeline
products across all the companies, current technology, molecule type, stage,
company finances, comparative analysis and therapeutic assessment at every
step. These Reports highlights therapeutic targets and their mode of action;
for instance Breast Cancer targets: PI3 Kinase inhibitors, Human Epidermal
Growth Factor Receptor 4 (HER-4/ERBB4) inhibitors, etc. and Lung Cancer
Targets: Cyclin Dependent Kinase (CDKs) inhibitors, Platelet Derived Growth
Factor (PDGF) inhibitors and many more. Moreover these reports can be
customized to include any specific information.
DelveInsight's reports
consist of 80+ MOA reports on the current “hot” oncology targets for which the
industry’s collective pipeline is brimming with drugs like on Breast cancer
(28%), Lung cancer (29%), Prostate cancer, Colorectal cancer and Melanoma of
which Breast cancer and Lung cancer collectively account for 57% of cancer
drugs in pipeline. Thus, making it the most known among the American clients.
These reports are
available through leading resellers such as Report Linker, Report Buyer, Market
Publishers, Research and Markets, Market Research, ASD Media and Report stack .
No comments:
Post a Comment